WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both…
Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period…
Los Angeles, USA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Liver Disease Pipeline: Insights into New Pipeline Therapies and Landscape; Future Key Pharma Companies…